Autopsy report · NCT06813157

Mesenchymal Stem Cells in the Treatment of Refractory Primary Immune Thrombocytopenia

“Due to corporate strategic adjustment.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Na

Sponsor

Guangzhou Bio-gene Technology Co., Ltd

Sponsor type

Industry

Conditions

ITP - Immune Thrombocytopenia

Interventions

MSC

Participants

0

Sites

1

Countries

China

Trials that died the same way

• IBI397 or Combination Therapies in Patients With Advanced Malignancies
  “Due to the company's development strategy adjustment” (82% match in meaning)
• Study of ONO-7914 Alone and in Combination With ONO-4538 in Patients With Solid Tumors
  “Due to strategic reasons” (78% match in meaning)
• Improving End-of-life Care by Continuing Medical Education and Electronic Decision Making Support for General Practitioners
  “due to organisational changes” (74% match in meaning)
• Safety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors.
  “Due to development strategy change.” (73% match in meaning)
• The Effect of Sodium Bicarbonate (Nephrotrans®) on Calcification Propensity of Serum in Kidney Transplant Recipients
  “due to organizational reason” (71% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.